PARIS — French drugmaker Sanofi-Aventis SA aims to double sales at its Sanofi Pasteur vaccines business by 2013, compared to the 2008 level, and reiterated it could make acquisitions in this fast-growing area.
Sanofi-Aventis raised its outlook for 2009 earlier this year because of rising sales of H1N1 flu shots, Reuters reported Dec. 17.
The manufacturer forecast that H1N1 vaccines would add about $500 million to its sales in the fourth quarter of this year and indicated sales would continue "at a similar rate" until into the first quarter of 2010.
Sanofi said in an investor presentation Dec. 17 that it was targeting $5.76 billion of net sales, including sales of the H1N1 flu vaccine, for 2010 for the vaccines business.
Sanofi Pasteur's vaccines offer protection against diseases such as flu, cholera and whooping cough.